Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

SWK Holdings' Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics

PR Newswire October 27, 2020

Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020

GlobeNewswire October 21, 2020

Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva(TM)* to treat dialysis patients with pruritus

GlobeNewswire October 20, 2020

Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer

GlobeNewswire October 1, 2020

Cara Therapeutics Reports Second Quarter 2020 Financial Results

GlobeNewswire August 10, 2020

Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

GlobeNewswire August 6, 2020

Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020

GlobeNewswire August 3, 2020

Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.

GlobeNewswire June 30, 2020

Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA(TM) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

GlobeNewswire June 17, 2020

Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 27, 2020

Cara Therapeutics Reports First Quarter 2020 Financial Results

GlobeNewswire May 11, 2020

Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference

GlobeNewswire May 7, 2020

Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020

GlobeNewswire May 4, 2020

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus

GlobeNewswire April 21, 2020

VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA(TM) injection in haemodialysis patients with Pruritus

Business Wire April 21, 2020

Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference

GlobeNewswire April 8, 2020

Cara Therapeutics Reports Clinical Updates

GlobeNewswire March 25, 2020

Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 27, 2020

Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

GlobeNewswire February 20, 2020

Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 8, 2020